Barclays’s VolitionRx Ltd VNRX Stock Holding History

Barclays’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-118	Closed	-$3.29K	–	4719
2023 Q2	$3.29K	Hold	118	–	–	﹤0.01%	4301
2023 Q1	$4.51K	Hold	118	–	–	﹤0.01%	4836
2022 Q4	$5.74K	Hold	118	–	–	﹤0.01%	4986
2022 Q3	$3K	Hold	118	–	–	﹤0.01%	4594
2022 Q2	$5K	Sell	118 -1,359	-92%	-$68.5K	﹤0.01%	4794
2022 Q1	$89K	Hold	1,477	–	–	﹤0.01%	3842
2021 Q4	$93K	Buy	1,477 +1,319	+835%	+$90K	﹤0.01%	3749
2021 Q3	$10K	Sell	158 -266	-63%	-$16.8K	﹤0.01%	4521
2021 Q2	$28K	Sell	424 -1,074	-72%	-$72.7K	﹤0.01%	4395
2021 Q1	$113K	Buy	1,498 +757	+102%	+$64.9K	﹤0.01%	3953
2020 Q4	$57K	Sell	741 -177	-19%	-$12.2K	﹤0.01%	4362
2020 Q3	$59K	Sell	918 -29	-3%	-$1.97K	﹤0.01%	4514
2020 Q2	$73K	Buy	+947	New	+$68.4K	﹤0.01%	4724
2019 Q4	–	Sell	-10	Closed	-$1K	–	6857
2019 Q3	$1K	Buy	+10	New	+$796	﹤0.01%	6620
2018 Q2	–	Hold	0	–	–	–	7320
2018 Q1	–	Hold	0	–	–	–	7358

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAMC

Spectrum Asset Management (California) Newport Beach, California $315M AUM 19.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Barclays's VNRX Position: Q3 2023 in Review

Barclays sold out of VolitionRx Ltd (VNRX) in Q3 2023, closing a stake of 118 shares — an estimated $3.29K sold.

Barclays first reported a position in VNRX in Q3 2019 and held it in 14 quarters. The position peaked at $113K in Q1 2021. 28 funds tracked by Wall St. Rank hold VNRX as of Q3 2023.

Barclays reported no remaining VolitionRx Ltd position as of Q3 2023 after selling out during the quarter.
Barclays sold 118 VolitionRx Ltd shares in Q3 2023, an estimated $3.29K.
Barclays first reported a position in VolitionRx Ltd in Q3 2019 and held it in 14 quarters.
Barclays's VolitionRx Ltd position peaked at $113K in Q1 2021.
28 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.